Compass Therapeutics (CMPX) Assets Average (2018 - 2026)

Compass Therapeutics has disclosed Assets Average across 9 years of filings, most recently posting $212.4 million for Q1 2026.

• Assets Average for Q1 2026 came in at $212.4 million, up 56.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $212.4 million (up 56.24% YoY), and the FY2025 annual result was $180.0 million, up 21.1% from the prior year.
• Assets Average came in at $212.4 million for Q1 2026 at Compass Therapeutics, down from $225.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $225.4 million in Q4 2025 to a low of $124.1 million in Q2 2025.
• The 5-year median for Assets Average is $159.0 million (2024), against an average of $164.3 million.
• Across the five-year window, Assets Average jumped 199.99% in 2022 and dropped 21.66% in 2025, its largest moves.
• Compass Therapeutics' Assets Average stood at $163.7 million in 2022, then slipped by 0.17% to $163.5 million in 2023, then decreased by 11.43% to $144.8 million in 2024, then jumped by 55.7% to $225.4 million in 2025, then decreased by 5.79% to $212.4 million in 2026.
• The last three Assets Average figures came in at $212.4 million (Q1 2026), $225.4 million (Q4 2025), and $174.0 million (Q3 2025), per Business Quant data.